Photo by wxshutterbug from unsplash
Highlights • The manuscript details the rationale, design and protocol for PARADIGM-2.• PARADIGM-2 comprises two parallel phase I, dose escalation studies of the PARP inhibitor olaparib in combination with radiotherapy… Click to show full abstract
Highlights • The manuscript details the rationale, design and protocol for PARADIGM-2.• PARADIGM-2 comprises two parallel phase I, dose escalation studies of the PARP inhibitor olaparib in combination with radiotherapy (for MGMT unmethylated patients) and radiotherapy-temozolomide (for MGMT methylated patients) in newly diagnosed glioblastoma.• This is a novel approach to phase I dose escalation trial design that maximises the potential for patients with glioblastoma to benefit from the addition of the radio- and chemosensitizing drug olaparib.
Journal Title: Clinical and Translational Radiation Oncology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!